about
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensusDevelopment of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panelRecent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesSelection for hepatic resection of colorectal liver metastases: expert consensus statementSystematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications.Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients.Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?Staging of biliary tract and primary liver tumors.Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative explorationPortal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiationHepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study.Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.Transhepatic portal vein embolization: anatomy, indications, and technical considerations.Long-term survival after surgical management of neuroendocrine hepatic metastases.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.Solitary colorectal liver metastasis: resection determines outcome.Risk factors for pancreatic cancer: case-control studyExtrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone.The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.Simultaneous lung resection via a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and lung metastases.Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.Volume regeneration of segments 2 and 3 after right portal vein embolization in patients undergoing two-stage hepatectomy.The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.The caudate lobe of the liver: implications of embryology and anatomy for surgery.Case 57: eosinophilic cholangiopathy.A role for curative surgery in the treatment of selected patients with metastatic breast cancer.I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.
P50
Q26784531-3095CA93-1121-4569-9D1C-B4313891CD5EQ27014926-8321BC03-F3AF-4D61-AAD4-AD4CEA689DFAQ28067408-FFB68093-3D07-4910-8AC3-2583B93D9B0DQ30415026-4C49AD97-ED75-43E1-AB2E-9764D2A1260EQ30424124-EDE8CCD3-080E-4139-8A6F-DD735E551201Q30432108-0FE5FBDF-087D-4973-A9D3-161380A399E2Q33361810-037A35EB-7874-4A56-857A-0F202B8F35ACQ33389221-F4F7417A-E6E1-41F2-9224-0056D209A987Q33436503-671DB2FB-ED7A-4E1C-B86D-D6773C08C700Q33558951-28C98A9A-11A8-47A1-89D2-85D752EAE9A9Q33558968-E6758605-0442-447C-BEBB-C368A63B4317Q33590511-DB7CBA39-13B4-4D1C-A954-C9BB77410C2CQ33621522-263A7421-9131-4E7A-8EFA-104CF5BA6EBBQ33773415-0C302245-9C7E-49C5-80BC-1E3F5CC60074Q33785906-F6B9E2A3-F17D-4861-9DCB-723D1B3904B7Q33859804-9A60E045-9AD5-4124-910D-810CCFBF0256Q33860986-8580BE2D-1B52-4CD7-B084-23A02E625756Q33909734-789E002C-5CE5-4210-8F6F-6AF543D9D4C1Q33928253-8CA73FE4-2D2B-4930-BC6C-8F8F54D1D6F1Q33986084-F6D45D19-2080-4EE0-B0CC-2BF223B220D6Q34008552-E886DA61-09B1-45C4-A254-F64913CA77AAQ34070129-0A512CA4-27C4-4379-B50C-4D6A6E34F56FQ34149835-DACF7D4E-7D4C-4A47-81C4-958C0C620718Q34528249-3BC70748-5949-4279-ABEB-5E807378F3C7Q34557044-E5A36B69-2C9E-4743-8916-CD574F5B9034Q34567525-79B8481E-D08A-4374-8197-E7D8A3A6626BQ34582332-AC8ED4A0-99B2-49FE-907A-E774D3991946Q34596314-7F474FD1-516E-416F-BF60-67AC6141F304Q34601654-C01DE2AB-19C8-413F-871F-FB0476691A03Q34620495-75FEE365-BC9D-4592-B82C-F8F5601A2F1CQ34640123-33D41A8D-DDD4-4458-A96A-E8A8C982D78DQ34671096-BF5426BC-D1EC-442C-A4AA-F2BBBA044955Q34732306-D63FB038-0106-4DEF-8FBF-6F1D545053A4Q34892632-EED1E25B-4D08-47D9-9553-E8B7B8B7A27DQ34957320-A87AA7B2-83B8-40AE-8728-B1C0CF94310AQ35073882-B2B0CBB3-9C0D-432D-9203-60DBEA21766EQ35095988-9F36A87B-F5BD-446E-A8EE-E087456B9C2BQ35139625-BE6CB3C9-F4E9-4E21-8A99-75CC92F2A4FDQ35208826-5DBA4121-362C-4ECB-B3B7-43817130831CQ35289603-5063CEF5-239D-4668-AEFF-33EEAB0E8495
P50
description
onderzoeker
@nl
name
Jean-Nicolas Vauthey
@ast
Jean-Nicolas Vauthey
@en
Jean-Nicolas Vauthey
@es
Jean-Nicolas Vauthey
@nl
Jean-Nicolas Vauthey
@sl
type
label
Jean-Nicolas Vauthey
@ast
Jean-Nicolas Vauthey
@en
Jean-Nicolas Vauthey
@es
Jean-Nicolas Vauthey
@nl
Jean-Nicolas Vauthey
@sl
prefLabel
Jean-Nicolas Vauthey
@ast
Jean-Nicolas Vauthey
@en
Jean-Nicolas Vauthey
@es
Jean-Nicolas Vauthey
@nl
Jean-Nicolas Vauthey
@sl
P214
P244
P106
P213
0000 0000 4752 5649
P214
P244
no2009004214
P31
P7859
lccn-no2009004214